- Home
- JAZZ vs OGE Comparison
JAZZ vs OGE Comparison
Compare JAZZ & OGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JAZZ
- OGE
- Stock Information
- Founded
- JAZZ 2003
- OGE 1902
- Country
- JAZZ Ireland
- OGE United States
- Employees
- JAZZ N/A
- OGE 2291
- Industry
- JAZZ Biotechnology: Pharmaceutical Preparations
- OGE Electric Utilities: Central
- Sector
- JAZZ Health Care
- OGE Utilities
- Exchange
- JAZZ Nasdaq
- OGE Nasdaq
- Market Cap
- JAZZ 8.2B
- OGE 9.4B
- IPO Year
- JAZZ 2007
- OGE N/A
- Fundamental
- Price
- JAZZ $138.54
- OGE $46.17
- Analyst Decision
- JAZZ Strong Buy
- OGE Buy
- Analyst Count
- JAZZ 14
- OGE 6
- Target Price
- JAZZ $180.14
- OGE $49.00
- AVG Volume (30 Days)
- JAZZ 670.8K
- OGE 1.0M
- Earning Date
- JAZZ 11-05-2025
- OGE 10-29-2025
- Dividend Yield
- JAZZ N/A
- OGE 3.61%
- EPS Growth
- JAZZ N/A
- OGE 19.03
- EPS
- JAZZ N/A
- OGE 2.43
- Revenue
- JAZZ $4,086,695,000.00
- OGE $3,215,200,000.00
- Revenue This Year
- JAZZ $5.70
- OGE $6.99
- Revenue Next Year
- JAZZ $6.16
- OGE $4.35
- P/E Ratio
- JAZZ N/A
- OGE $19.22
- Revenue Growth
- JAZZ 4.52
- OGE 16.01
- 52 Week Low
- JAZZ $95.49
- OGE $39.10
- 52 Week High
- JAZZ $148.06
- OGE $47.33
- Technical
- Relative Strength Index (RSI)
- JAZZ 62.66
- OGE 54.80
- Support Level
- JAZZ $134.09
- OGE $46.25
- Resistance Level
- JAZZ $139.75
- OGE $47.00
- Average True Range (ATR)
- JAZZ 3.08
- OGE 0.64
- MACD
- JAZZ -0.21
- OGE 0.04
- Stochastic Oscillator
- JAZZ 83.51
- OGE 41.41
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
About OGE OGE Energy Corp
OGE Energy is a holding company for Oklahoma Gas & Electric, a regulated utility with electricity generation, transmission, and distribution service for 900,000 customers in Oklahoma and western Arkansas. In December 2021, OGE divested its 25.5% stake in Enable Midstream Partners, an oil and gas services company it created in 2013 through a unit exchange merger with Energy Transfer. OGE sold its 95.4 million limited partner units of Energy Transfer throughout 2022. OGE sold its retail gas business in 1928 and no longer has any gas operations.